Wednesday, February 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Barrick Gold’s Strategic Ambitions Face Partner Pushback

SiterGedge by SiterGedge
February 11, 2026
in Analysis, Commodities, Earnings, Gold & Precious Metals, Mergers & Acquisitions
0
Barrick Stock
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

While Barrick Gold’s latest financial results paint a picture of robust health, a significant strategic hurdle has emerged. The mining giant’s plan to spin off part of its North American operations is facing public opposition from its most important partner, Newmont Corporation, casting a shadow over an otherwise stellar performance.

Operational Performance Shines in Q4

The company’s operational strength was on full display in its fourth-quarter 2025 report, released on February 5. The figures comfortably exceeded market expectations, driven by a combination of solid production and historically elevated gold prices.

Key financial highlights included:
* Revenue: $6.00 billion, representing a 65% year-over-year increase.
* Earnings: Adjusted earnings per share came in at $1.04, decisively beating analyst estimates of $0.90.
* Cash Flow: Operating cash flow was a robust $2.73 billion.

Looking ahead, Barrick’s financial model for the full year 2026 is based on an assumed gold price of $4,500 per ounce, with all-in sustaining costs (AISC) projected to be between $1,760 and $1,950 per ounce.

Shareholders Reap Rewards of Strong Cash Generation

This powerful cash generation has led to a substantial capital return program for shareholders. The board approved a quarterly dividend of $0.42 per share, a 140% increase from the previous quarter.

Furthermore, management has instituted a new, formalized capital return framework. Under this policy, 50% of annual free cash flow will be returned to shareholders, comprising a fixed base dividend and a performance-linked component paid at year-end. Complementing this, the company executed $1.5 billion in share buybacks over the past year.

Should investors sell immediately? Or is it worth buying Barrick?

Leadership and Geopolitical Clarity Achieved

Barrick also resolved two significant uncertainties. Mark Hill, who had been serving as interim CEO since September 2025, has been formally appointed to the role on a permanent basis. Additionally, a protracted dispute with Mali’s military government was settled in November 2025. A payment of approximately $430 million secured the company’s continued control over the critical Loulo-Gounkoto complex and resulted in the release of detained personnel.

Partnership Dispute Threatens Key Strategic Initiative

Despite this positive backdrop, a conflict with joint venture partner Newmont now takes center stage. The dispute erupted when Newmont issued a sharply worded statement criticizing Barrick’s preparations for an initial public offering (IPO).

Barrick intends to list a minority stake (10-15%) of its North American gold assets by the end of 2026. This portfolio includes the crown jewel, Nevada Gold Mines, a joint venture in which Barrick holds a 61.5% interest and Newmont owns 38.5%.

Newmont has publicly criticized what it calls a “deterioration in performance and asset value” at Nevada Gold Mines over the past six years. The partner is insisting on the enforcement of contractual protective rights. Market analysts interpret this as a clear threat that Newmont could attempt to block the IPO through pre-emptive rights or consent clauses, with the stated goal of reversing the alleged underperformance.

With its leadership settled and a strong balance sheet, Barrick’s immediate challenge is navigating this partnership rift. The successful execution of the planned partial IPO by late 2026 now appears heavily contingent on reaching an agreement with its joint venture partner.

Ad

Barrick Stock: Buy or Sell?! New Barrick Analysis from February 11 delivers the answer:

The latest Barrick figures speak for themselves: Urgent action needed for Barrick investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 11.

Barrick: Buy or sell? Read more here...

Tags: Barrick
SiterGedge

SiterGedge

Related Posts

Diffusion Pharmaceuticals Stock
Analysis

CervoMed’s Strategic Pivot: A Clinical-Stage Biotech Eyes Phase 3 Milestone

February 11, 2026
Graphite One Stock
Analysis

Graphite One Equity Offering Triggers Share Price Decline

February 11, 2026
Ekso Bionics Holdings Stock
Analysis

Ekso Bionics: A Pivotal Period Ahead as Key Catalysts Approach

February 11, 2026
Next Post
Diffusion Pharmaceuticals Stock

CervoMed's Strategic Pivot: A Clinical-Stage Biotech Eyes Phase 3 Milestone

AIM ImmunoTech Stock

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline

Recommended

NET stock news

Dover Co. Sees Significant Drop in Short Interest and Demonstrates Resilience in Challenging Times

3 years ago
Ocugen Stock

Ocugen’s Gene Therapy Strategy Aligns with Projected Boom in Retinal Biologics Market

6 months ago
Healthcare Services Stock Exchange

BioSig Technologies PURE EP Platform Revolutionizing Cardiac Healthcare with Near Field Tracking Algorithm

2 years ago
Hartford Services Stock

Hartford Financial Services Exceeds Market Expectations with Strong Q4 2025

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Graphite One Equity Offering Triggers Share Price Decline

Strategic Investor Acquires Significant Stake in enVVeno Medical

Ekso Bionics: A Pivotal Period Ahead as Key Catalysts Approach

Final Chapter for 23andMe’s Corporate Shell as Bankruptcy Wraps Up

Enzo Biochem Concludes Transition to Private Ownership

Solana’s Strategic Pivot: A High-Stakes Institutional Push

Trending

AIM ImmunoTech Stock
IPOs

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline

by SiterGedge
February 11, 2026
0

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm...

Diffusion Pharmaceuticals Stock

CervoMed’s Strategic Pivot: A Clinical-Stage Biotech Eyes Phase 3 Milestone

February 11, 2026
Barrick Stock

Barrick Gold’s Strategic Ambitions Face Partner Pushback

February 11, 2026
Graphite One Stock

Graphite One Equity Offering Triggers Share Price Decline

February 11, 2026
enVVeno Medical Stock

Strategic Investor Acquires Significant Stake in enVVeno Medical

February 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline
  • CervoMed’s Strategic Pivot: A Clinical-Stage Biotech Eyes Phase 3 Milestone
  • Barrick Gold’s Strategic Ambitions Face Partner Pushback

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com